News

01/04/14
GREER® Laboratories, Inc. Announces FDA Approval of ORALAIR®, the First Sublingual Allergy Immunotherapy Tablet, for the Treatment of Grass Pollen Allergy

ORALAIR® (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue...

[more]

 

STALLERGENES, A GLOBAL ALLERGY PLAYER THAT PLACES PATIENTS AT THE HEART OF ITS STRATEGY

Drawing on its in-depth knowledge of allergic diseases, and its unique expertise in allergy immunotherapy (AIT) for more than 50 years, Stallergenes thereby offers a comprehensive approach to improving the lives of allergy patients. 

 

Patient expectations are at the core of Stallergenes innovation strategy. World leader in sublingual immunotherapy, Stallergenes provides efficient and patient-friendly allergy immunotherapy treatment options, such as shorter protocols to reduce the duration of treatment and the new convenient tablet form.

 

For more information, please visit Stallergenes' corporate website.